Kearns-Sayre Syndrome
Also known as: KSS, Ophthalmoplegia-plus syndrome
Kearns-Sayre Syndrome (KSS) is a rare mitochondrial disorder characterized by progressive external ophthalmoplegia (PEO), pigmentary retinopathy, and onset before age 20. It often involves cardiac conduction defects, cerebellar ataxia, and elevated cerebrospinal fluid protein. KSS results from large-scale deletions of mitochondrial DNA (mtDNA).
Kearns-Sayre Syndrome is a rare problem where your body's energy factories (mitochondria) don't work right. It makes your eyes droopy and causes other problems like heart issues and muscle weakness. Doctors can help manage the symptoms, but there's no cure.
Signs & Symptoms
- Progressive external ophthalmoplegia (PEO)
- Pigmentary retinopathy
- Cardiac conduction defects (heart block)
- Cerebellar ataxia
- Elevated cerebrospinal fluid (CSF) protein
- Muscle weakness
- Short stature
- Hearing loss
- Diabetes mellitus
- Renal tubular acidosis
- Endocrine abnormalities
Treatment Options
Coenzyme Q10 (CoQ10)
SUPPORTIVEL-Carnitine
SUPPORTIVECardiac pacemaker
HIGHLY EFFECTIVEHearing aids
HIGHLY EFFECTIVEPhysical therapy
SUPPORTIVEOccupational therapy
SUPPORTIVEManagement of endocrine abnormalities (e.g., diabetes, hypoparathyroidism)
HIGHLY EFFECTIVEDiagnosis
- Clinical evaluation
- Neurological examination
- Ophthalmological examination
- Electrocardiogram (ECG)
- Electrophysiological studies (EMG)
- Muscle biopsy (to assess mitochondrial function and mtDNA deletions)
- Cerebrospinal fluid (CSF) analysis
- Genetic testing (mtDNA deletion analysis)
History
Kearns-Sayre Syndrome was first described in 1958 by Thomas P. Kearns and George P. Sayre, who reported two patients with progressive external ophthalmoplegia, pigmentary retinopathy, and cardiac conduction defects.
Recent Breakthroughs
Gene Therapy Approaches for Mitochondrial Diseases
Research is ongoing to develop gene therapy strategies to correct or compensate for mtDNA mutations. While still in early stages, some preclinical studies have shown promise in delivering functional genes to mitochondria.
Novel Therapeutic Targets for Mitochondrial Dysfunction
Studies are identifying new therapeutic targets to improve mitochondrial function and reduce oxidative stress in KSS and other mitochondrial disorders. These include compounds that enhance mitochondrial biogenesis and improve electron transport chain efficiency.